| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1011542536 |
| P356 | DOI | 10.1186/1471-2415-13-18 |
| P932 | PMC publication ID | 3639939 |
| P698 | PubMed publication ID | 23617902 |
| P5875 | ResearchGate publication ID | 236337091 |
| P2093 | author name string | Alastair K Denniston | |
| Andrew D Dick | |||
| P2860 | cites work | Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib | Q24594790 |
| Emerging drugs for uveitis | Q24630848 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity | Q24652600 | ||
| Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop | Q24727581 | ||
| Mycophenolate mofetil therapy for inflammatory eye disease | Q46629616 | ||
| Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis | Q47343514 | ||
| Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis | Q47728793 | ||
| Epidemiology of endogenous uveitis in south-western Finland. | Q50612036 | ||
| Visual functioning and general health status in patients with uveitis. | Q51966015 | ||
| Interobserver agreement in grading activity and site of inflammation in eyes of patients with uveitis. | Q53042402 | ||
| Development of a questionnaire for measurement of vision-related quality of life. | Q53559921 | ||
| Effect of infliximab on sight-threatening panuveitis in Behçet's disease. | Q54153155 | ||
| Cystic fibrosis | Q55881299 | ||
| Analysis of 14 cystic fibrosis mutations in five South European populations | Q57304799 | ||
| Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina | Q59400563 | ||
| Anti-TNF-α therapy for uveitis: Behçet and beyond | Q60207426 | ||
| Cyclosporin A: Alterations of the Cellular Immune Response in S-Antigen-Induced Experimental Autoimmune Uveitis | Q61443385 | ||
| Modulation of Experimental Autoimmune Uveitis With Cyclosporin A | Q61443400 | ||
| Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis | Q67938095 | ||
| Cyclophosphamide therapy of Behcet's disease | Q68433835 | ||
| Cyclosporine therapy for uveitis: long-term followup | Q69879848 | ||
| Inhibition of experimental autoimmune uveoretinitis by mycophenolate mofetil, an inhibitor of purine metabolism | Q70868868 | ||
| Treatment of uveitis with azathioprine (Imuran) | Q70976589 | ||
| Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents | Q71020371 | ||
| A clinical trial of FK506 in refractory uveitis | Q72082849 | ||
| Cyclophosphamide Therapy of Peripheral Uveitis | Q72403833 | ||
| Treatment of intraocular inflammatory disease with cyclosporin A | Q72556437 | ||
| Methotrexate treatment of uveal disease | Q72763301 | ||
| Rescue therapy with mycophenolate mofetil in refractory uveitis | Q77506715 | ||
| Adaptive clinical trials: the promise and the caution | Q82966805 | ||
| Treat early and embrace the evidence in favour of anti-TNF-alpha therapy for Behçet's uveitis | Q83160921 | ||
| Infliximab therapy for refractory uveitis: 2-year results of a prospective trial | Q84022834 | ||
| Standardization of vitreal inflammatory activity in intermediate and posterior uveitis | Q93559746 | ||
| Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials | Q95483222 | ||
| Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy | Q28244849 | ||
| EuroQol--a new facility for the measurement of health-related quality of life | Q29547873 | ||
| Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study | Q33321092 | ||
| Cyclophosphamide for ocular inflammatory diseases | Q33517496 | ||
| Cyclosporine for ocular inflammatory diseases | Q33520584 | ||
| Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients | Q33774951 | ||
| Development of the 25-item National Eye Institute Visual Function Questionnaire | Q34083677 | ||
| Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study | Q34305621 | ||
| Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial | Q35319079 | ||
| Scale for photographic grading of vitreous haze in uveitis | Q35563918 | ||
| A CFTR potentiator in patients with cystic fibrosis and the G551D mutation | Q35591553 | ||
| Quality of life and visual function in patients with intermediate uveitis | Q35593666 | ||
| Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis | Q35763000 | ||
| Validating the SF-36 health survey questionnaire: new outcome measure for primary care | Q35823601 | ||
| Uveitis: a potentially blinding disease. | Q35838711 | ||
| The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). | Q35896779 | ||
| Associations among visual acuity and vision- and health-related quality of life among patients in the multicenter uveitis steroid treatment trial | Q35921417 | ||
| A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease | Q35945533 | ||
| Cyclosporin a. Inhibition of experimental autoimmune uveitis in Lewis rats | Q36998081 | ||
| Biologics in the treatment of uveitis | Q37046546 | ||
| Methotrexate for ocular inflammatory diseases | Q37204512 | ||
| Causes and frequency of blindness in patients with intraocular inflammatory disease | Q37319691 | ||
| Azathioprine for ocular inflammatory diseases | Q37366679 | ||
| Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience | Q37650221 | ||
| The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions | Q37696090 | ||
| Adaptive clinical trials in oncology | Q37953783 | ||
| Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease | Q37961028 | ||
| Non-syndromic retinal ciliopathies: translating gene discovery into therapy | Q38030482 | ||
| A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. | Q39645988 | ||
| Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors. | Q43048775 | ||
| Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease | Q44783874 | ||
| Survey of expert practice and perceptions of the supporting clinical evidence for the management of uveitis-related cataract and cystoid macular oedema | Q44835234 | ||
| Multicenter study of infliximab for refractory uveoretinitis in Behçet disease | Q44844090 | ||
| Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. | Q46481520 | ||
| Mycophenolate mofetil for the treatment of uveitis | Q46613125 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hormone | Q11364 |
| anti-inflammatory agent | Q581996 | ||
| eye disease | Q3041498 | ||
| immunosuppressive drug | Q249619 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 18 | |
| P577 | publication date | 2013-04-24 | |
| P1433 | published in | BMC Ophthalmology | Q15765692 |
| P1476 | title | Systemic therapies for inflammatory eye disease: past, present and future | |
| P478 | volume | 13 |
| Q47958511 | An overview of the clinical applications of optical coherence tomography angiography |
| Q38395263 | Autoimmune uveitis: clinical, pathogenetic, and therapeutic features. |
| Q36067976 | Automated Analysis of Vitreous Inflammation Using Spectral-Domain Optical Coherence Tomography |
| Q92691394 | Cochrane corner: why we still don't know whether anti-TNF biologic therapies impact uveitic macular oedema |
| Q26771638 | Drug discovery in ophthalmology: past success, present challenges, and future opportunities |
| Q26796779 | Heterogeneity of primary outcome measures used in clinical trials of treatments for intermediate, posterior, and panuveitis |
| Q35994694 | Immunopharmacotherapy of non-infectious uveitis: where do we stand? |
| Q35866363 | Objective measurement of vitreous inflammation using optical coherence tomography |
| Q39008193 | Ocular inflammation and endoplasmic reticulum stress are attenuated by supplementation with grape polyphenols in human retinal pigmented epithelium cells and in C57BL/6 mice. |
| Q49479819 | Optimizing OCT acquisition parameters for assessments of vitreous haze for application in uveitis. |
| Q34274075 | Pharmacotherapy for uveitis: current management and emerging therapy |
| Q53107185 | Quantitative analysis of vitreous inflammation using optical coherence tomography in patients receiving sub-Tenon's triamcinolone acetonide for uveitic cystoid macular oedema. |
| Q48423086 | Reversible lesion involving the splenium of the corpus callosum caused by phenytoin sodium withdrawal |
| Q48280517 | Reversible splenial lesion and complex visual disturbances due to carbamazepine withdrawal. |
| Q55260506 | mTOR-inhibiting pharmacotherapy for the treatment of non-infectious uveitis: a systematic review protocol. |
Search more.